Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Total Non-Current Liabilities (2021 - 2025)

Historic Total Non-Current Liabilities for Indivior Pharmaceuticals (INDV) over the last 5 years, with Q3 2025 value amounting to $1.6 billion.

  • Indivior Pharmaceuticals' Total Non-Current Liabilities rose 22104.86% to $1.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 billion, marking a year-over-year increase of 22104.86%. This contributed to the annual value of $1.6 billion for FY2024, which is 15177.2% up from last year.
  • Indivior Pharmaceuticals' Total Non-Current Liabilities amounted to $1.6 billion in Q3 2025, which was up 22104.86% from $1.7 billion recorded in Q2 2025.
  • Indivior Pharmaceuticals' Total Non-Current Liabilities' 5-year high stood at $1.7 billion during Q2 2025, with a 5-year trough of -$1.5 billion in Q3 2023.
  • Over the past 5 years, Indivior Pharmaceuticals' median Total Non-Current Liabilities value was $674.0 million (recorded in 2022), while the average stood at $182.8 million.
  • In the last 5 years, Indivior Pharmaceuticals' Total Non-Current Liabilities tumbled by 1527.27% in 2022 and then soared by 24539.82% in 2025.
  • Over the past 5 years, Indivior Pharmaceuticals' Total Non-Current Liabilities (Quarter) stood at $825.0 million in 2021, then fell by 15.27% to $699.0 million in 2022, then fell by 7.15% to $649.0 million in 2023, then skyrocketed by 151.77% to $1.6 billion in 2024, then dropped by 2.51% to $1.6 billion in 2025.
  • Its last three reported values are $1.6 billion in Q3 2025, $1.7 billion for Q2 2025, and $1.6 billion during Q1 2025.